TSH: What Your Number Changes About Your Treatment

What TSH Actually Measures, and Why It Matters for Women

TSH is produced by your pituitary gland, not your thyroid. It acts like a thermostat signal: when thyroid hormone levels in your blood drop, your pituitary pumps out more TSH to push the thyroid to produce more. When thyroid levels run high, TSH falls. This feedback loop is why TSH is the most sensitive early warning of thyroid trouble, often shifting out of range before T4 or T3 do.

Women are 5 to 8 times more likely than men to develop thyroid disease, a gap that widens across reproductive transitions. The autoimmune mechanisms behind Hashimoto's thyroiditis and Graves' disease are influenced by estrogen and progesterone, and thyroid function is further stressed by pregnancy, postpartum recovery, and the hormonal shifts of perimenopause. Knowing your TSH number is not a purely academic exercise. It directly changes what your clinician prescribes, at what dose, and how urgently.

How the Test Is Done

TSH is measured from a standard blood draw. No fasting is required for TSH alone, though if your panel includes a lipid screen or fasting glucose, you will fast anyway. The result is reported in mIU/L (milli-international units per liter). Most commercial labs use an immunoassay method; third-generation assays can detect TSH as low as 0.01 mIU/L, which matters when you are monitoring suppressive therapy for thyroid cancer.

Why "Normal" Is Not One-Size-Fits-All

The population-derived reference range of roughly 0.45 to 4.5 mIU/L comes from studies of apparently healthy adults. But that pool includes people with undiagnosed early thyroid disease, which shifts the upper end upward. The American Association of Clinical Endocrinology (AACE) has suggested a narrower normal of 0.3 to 3.0 mIU/L, though this remains debated. For you as an individual, the most useful "normal" is one interpreted against your symptoms, age, antibody status, and reproductive plans.

What a High TSH Means for Your Health and Your Treatment

A TSH above the upper reference limit means your pituitary is working overtime to stimulate a thyroid that isn't keeping up. The clinical label is hypothyroidism. The most common cause in women is Hashimoto's thyroiditis, an autoimmune condition in which antibodies (anti-TPO and anti-thyroglobulin) slowly damage thyroid tissue.

Symptoms overlap with a range of female-specific conditions: heavy or irregular periods, fatigue, brain fog, weight gain, dry skin, hair thinning, and low mood. Because these symptoms also describe perimenopause, PCOS, anemia, and depression, thyroid disease is frequently missed or attributed to something else.

Overt Hypothyroidism (TSH above 10 mIU/L)

Treatment is nearly always indicated at this level. Standard therapy is oral levothyroxine (T4), dosed by weight at approximately 1.6 mcg/kg/day to start, then titrated to bring TSH into range. Women generally tolerate and metabolize levothyroxine similarly to men, but there are important exceptions at specific life stages described below.

Subclinical Hypothyroidism (TSH 4.5 to 10 mIU/L, normal T4)

This is where clinical decisions become more nuanced. The USPSTF 2015 evidence review found insufficient evidence to recommend universal screening in non-pregnant adults, but treatment decisions should still be individualized. For women in this range who have symptoms, positive anti-TPO antibodies, or who are trying to conceive or pregnant, most guidelines recommend initiating levothyroxine. For asymptomatic women over 65, watchful waiting may be appropriate because TSH naturally rises slightly with age.

Hashimoto's Thyroiditis: The Female-Predominant Autoimmune Driver

Hashimoto's affects roughly 5% of the general population and is 7 to 10 times more common in women. Positive anti-TPO antibodies confirm the autoimmune diagnosis and change the treatment calculus even when TSH is only mildly elevated. Women with Hashimoto's and TSH values between 2.5 and 4.5 mIU/L who are experiencing symptoms or are trying to conceive may benefit from low-dose levothyroxine, a decision made case by case.

What a Low TSH Means for Your Health and Your Treatment

A TSH below the lower reference limit means your pituitary has detected too much thyroid hormone and has throttled back. The clinical label is hyperthyroidism. The most common cause in women of reproductive age is Graves' disease, another autoimmune condition in which TSH-receptor antibodies mimic TSH and keep the thyroid in constant overdrive.

Symptoms include palpitations, anxiety, heat intolerance, weight loss despite normal or increased appetite, lighter or absent periods, and sometimes eye changes (in Graves'). These, too, can be confused with perimenopause, anxiety disorder, or stimulant use.

Overt Hyperthyroidism (TSH <0.1 mIU/L)

Treatment options include antithyroid drugs (methimazole is first-line in non-pregnant adults; propylthiouracil, or PTU, is preferred in the first trimester), radioactive iodine ablation, and thyroidectomy. The choice depends on cause, severity, reproductive plans, and preference. Women planning pregnancy within six months should generally avoid radioactive iodine.

Subclinical Hyperthyroidism (TSH 0.1 to 0.45 mIU/L, normal T4 and T3)

Not all low-TSH states require medication. Some women, particularly those over 65 or those with cardiac risk factors or reduced bone density, benefit from treatment even at subclinical levels because subclinical hyperthyroidism triples the risk of atrial fibrillation and accelerates bone loss. Younger, asymptomatic women with no cardiac risk may be monitored without treatment initially.

Over-Suppression from Levothyroxine

A low TSH in a woman already taking levothyroxine usually means her dose is too high. The fix is straightforward: reduce the dose and recheck in six to eight weeks. Chronic suppression accelerates bone turnover and raises fracture risk, an especially important consideration after menopause when baseline bone density is already falling.

TSH Across Your Reproductive Life Stages

This framework for interpreting TSH by reproductive stage is not something you'll find consolidated in a single clinical guideline. It is synthesized from ACOG, the American Thyroid Association (ATA), and The Menopause Society's respective guidance, bridged specifically for the woman reading this.

Reproductive Years (Ages 18 to 40, Not Pregnant)

The standard range of 0.45 to 4.5 mIU/L applies, but symptoms and anti-TPO status should drive treatment decisions at the margins. Hypothyroidism can disrupt the menstrual cycle by raising prolactin and altering GnRH pulsatility, causing irregular or heavy periods, anovulation, and luteal phase defects. Restoring TSH to the lower half of the normal range often normalizes the cycle.

PCOS and thyroid disease frequently co-occur. A 2014 study in the Journal of Clinical Endocrinology found that women with PCOS had significantly higher TSH values than age-matched controls, and Hashimoto's antibodies were more prevalent in the PCOS group. If you have PCOS and unexplained weight gain, fatigue, or worsening cycle irregularity, TSH testing is warranted even if a prior result was "normal."

Trying to Conceive

The ATA recommends a pre-conception TSH target of below 2.5 mIU/L for women with known thyroid disease or positive anti-TPO antibodies who are actively trying to conceive. Hypothyroidism impairs ovulation and implantation. Even subclinical hypothyroidism is associated with higher rates of miscarriage and reduced IVF success rates. If you are working with a reproductive endocrinologist, expect TSH to be measured at the start of every stimulation cycle.

Pregnancy (First, Second, and Third Trimesters)

Thyroid demands increase sharply in early pregnancy because hCG (human chorionic gonadotropin) cross-reacts with TSH receptors and stimulates the thyroid directly. At the same time, the growing fetus depends entirely on maternal thyroid hormone for the first 10 to 12 weeks of gestation, before its own thyroid is functional.

ACOG and the ATA recommend trimester-specific TSH targets:

• First trimester: TSH <2.5 mIU/L
• Second trimester: TSH <3.0 mIU/L
• Third trimester: TSH <3.5 mIU/L

Women already on levothyroxine typically need a dose increase of 25 to 30% as soon as pregnancy is confirmed, sometimes before the first prenatal visit. Untreated hypothyroidism in pregnancy is associated with preeclampsia, preterm delivery, placental abruption, and impaired fetal neurodevelopment. These are not rare edge cases; they are the reason thyroid screening in pregnancy is standard of care.

The landmark CATS trial (Controlled Antenatal Thyroid Screening, published in NEJM) found that universal screening and treatment of subclinical hypothyroidism in pregnancy did not significantly improve child cognitive outcomes at age 3, but the trial has been criticized for treating women too late (median 13 weeks). The debate continues, and most clinicians now lean toward earlier intervention rather than watchful waiting.

Hyperthyroidism in pregnancy requires careful drug selection. Methimazole is avoided in the first trimester because of a small but real risk of embryopathy (aplasia cutis, choanal atresia). PTU is the preferred antithyroid drug in the first trimester per ATA guidelines, after which the switch back to methimazole may be considered. Both drugs cross the placenta and can suppress fetal thyroid function, so the goal is to use the lowest effective dose that keeps free T4 in the upper-normal range.

Postpartum and Lactation

Postpartum thyroiditis (PPT) affects 5 to 10% of women in the first year after delivery. It typically follows a triphasic pattern: a transient hyperthyroid phase (low TSH, weeks 1 to 4 postpartum), followed by a hypothyroid phase (high TSH, months 4 to 8), and usually resolution. About 20 to 40% of women with PPT do not fully recover and develop permanent hypothyroidism, particularly those with positive anti-TPO antibodies at delivery.

Levothyroxine is safe during breastfeeding. It transfers into breast milk in very small amounts that are clinically insignificant and do not affect infant thyroid function. Methimazole and PTU also transfer into breast milk, but at low levels; most guidelines consider methimazole at doses below 20 mg/day compatible with breastfeeding, with infant monitoring recommended.

Postpartum depression and PPT share symptoms including fatigue, low mood, and cognitive slowing. A TSH check at the 6-week postpartum visit helps distinguish between them and prevents months of unnecessary suffering.

Perimenopause and Menopause

Hot flashes, sleep disruption, weight gain, mood changes, brain fog, and hair thinning happen in both thyroid disease and menopause transition. A TSH result outside the normal range does not mean symptoms are "just thyroid," and a normal TSH does not rule out menopausal symptoms requiring treatment. Both conditions can exist simultaneously.

The Menopause Society (formerly NAMS) recommends that clinicians distinguish thyroid disease from menopause rather than attributing all symptoms to one or the other. A TSH drawn when symptoms first appear gives a baseline that informs whether future symptom shifts reflect thyroid change or hormonal transition.

After menopause, estrogen therapy (oral) raises thyroxine-binding globulin (TBG), which binds more T4 and can effectively raise TSH in women on levothyroxine. Women starting oral hormone therapy who are already on levothyroxine may need a dose increase, confirmed by retesting TSH 6 to 8 weeks after initiating HRT. Transdermal estrogen does not significantly affect TBG and is less likely to require a levothyroxine dose adjustment.

Pregnancy and Lactation Safety (Required Summary)

This section consolidates the key safety points for women who are pregnant, planning pregnancy, or breastfeeding.

Levothyroxine in pregnancy: Safe and required when TSH is above trimester-specific targets. Doses typically increase 25 to 30% in the first trimester. Untreated hypothyroidism poses greater risk to the fetus than the medication itself.

PTU in the first trimester: Preferred antithyroid drug in the first trimester for hyperthyroidism. Associated with a small risk of maternal hepatotoxicity; switch to methimazole after the first trimester if hyperthyroidism remains active.

Methimazole in pregnancy: Avoid in the first trimester because of embryopathy risk. Acceptable from the second trimester onward, at the lowest effective dose.

Radioactive iodine (RAI): Absolutely contraindicated in pregnancy. RAI is also contraindicated while breastfeeding and requires cessation of breastfeeding if used.

Breastfeeding: Levothyroxine is compatible with breastfeeding. Methimazole up to 20 mg/day and PTU up to 300 mg/day are generally compatible, with infant thyroid monitoring advised.

Contraception note: Women being treated for Graves' disease with methimazole or PTU who wish to delay pregnancy should use reliable contraception. Active, uncontrolled hyperthyroidism during conception is associated with miscarriage, fetal growth restriction, and preterm delivery. Achieving euthyroidism before conception is strongly advised.

Who This Is Right For, and Who Should Wait

Women Who Likely Need Treatment Now

• TSH above 10 mIU/L at any life stage with overt symptoms
• TSH above 2.5 mIU/L in the first trimester of pregnancy
• TSH above 4.5 mIU/L while trying to conceive, especially with positive anti-TPO antibodies
• TSH below 0.1 mIU/L with free T4 elevation, any life stage
• Subclinical hyperthyroidism in a woman over 65 with osteoporosis or cardiac risk

Women Who May Monitor First

• Asymptomatic subclinical hypothyroidism (TSH 4.5 to 10 mIU/L) in a woman over 65 with no fertility goals and no anti-TPO antibodies
• Mildly low TSH (0.1 to 0.45 mIU/L) in a young asymptomatic woman with no cardiac history, pending repeat testing in 3 months
• TSH at the upper end of normal (3.0 to 4.5 mIU/L) with no symptoms and no antibodies, not pregnant and not trying to conceive

The Evidence Gap in Women

Women have been included in most major thyroid trials, but subgroup analyses by reproductive stage are sparse. The Whickham Survey, the foundational epidemiological study of thyroid disease in the UK, enrolled both sexes but did not stratify outcomes by menstrual cycle phase or hormonal status. TSH reference ranges used by most labs today were largely derived from mixed-sex, predominantly white populations. Reference intervals for Black, Hispanic, and Asian women may differ, and the data on this are still limited. When your clinician says your TSH is "borderline," that judgment is based on population-level averages that may not perfectly reflect your physiology.

How Your TSH Number Changes the Prescription

Your TSH result does not exist in isolation. Here is how it maps directly to clinical action:

| TSH Result | Most Likely Meaning | Typical Next Step | |---|---|---| | <0.1 mIU/L | Overt hyperthyroidism | Free T4/T3, TSH-receptor antibodies, treatment | | 0.1 to 0.45 mIU/L | Subclinical hyperthyroidism | Repeat in 3 months, consider treatment if >65 or bone/cardiac risk | | 0.45 to 2.5 mIU/L | Optimal range | No change; lower end preferred if pregnant or TTC | | 2.5 to 4.5 mIU/L | Borderline; context-dependent | Treat if pregnant, TTC, or symptomatic with anti-TPO+ | | 4.5 to 10 mIU/L | Subclinical hypothyroidism | Add free T4, anti-TPO; treat if symptomatic or pregnant | | >10 mIU/L | Overt hypothyroidism | Start levothyroxine; dose ~1.6 mcg/kg/day |

Monitoring frequency after starting or adjusting levothyroxine is typically every 6 to 8 weeks until TSH stabilizes, then every 6 to 12 months once you are in your target range. In pregnancy, TSH is rechecked every 4 weeks through mid-gestation, then once in the third trimester.

If your TSH is abnormal on a first test, a single repeat 2 to 4 weeks later before initiating treatment is reasonable in non-urgent situations. TSH can shift temporarily with illness, calorie restriction, or certain medications (notably biotin supplementation at high doses can falsely suppress TSH on some immunoassay platforms; stop biotin at least 48 hours before your draw).